Cofactor Genomics, a predictive immune modeling company, today presented initial results from the multi-center clinical study PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-Treatment Tumor Biopsies) at this week’s Advances in Genome Biology and Technology Precision Health Meeting. The data shows that Cofactor’s OncoPrism assay with Predictive Immune Modeling was nearly twice as accurate as PD-L1 assays in identifying patients who would benefit from immunotherapies such as Keytruda (pembrolizumab).
To view the full announcement, including downloadable images, bios and more, click here.
The central theses:
- Data presented at AGBT Precision Health shows that Cofactor’s technology provides more predictive results than PD-L1 assays
- OncoPrism-HNSCC outperforms PD-L1 in patient cohorts from multi-site, decentralized clinical trials
- Cofactor’s multidimensional biomarker approach will be used in the PREDAPT study in 11 types of cancer
Click on the image above to view the full announcement.
About PREDAPT
Predicting Immunotherapy Efficacy From Analysis of Pre-Treatment Tumor Biopsies (PREDAPT) is a national clinical trial sponsored by Cofactor Genomics in collaboration with leading provider of decentralized clinical trials, CureBase. The aim of the study is to evaluate the predictive power of Cofactor’s Predictive Immune Modeling approach and the generated biomarkers to predict which patients across 11 cancer types will ultimately benefit from immune checkpoint inhibitors.
About cofactor genomics
Cofactor Genomics bridges the gap in precision medicine by developing diagnostic tools to match the right patient with the right treatment at the right time. Predicting patient response to therapy currently relies on isolated single-analyte biomarkers that have failed to accurately predict therapy response, resulting in unnecessary healthcare costs and, worst of all, negative patient outcomes. Cofactor’s products use Predictive Immune Modeling, which uses RNA…
[ad_2]
Source story
